Aradigm Corporation  

(Public, NASDAQ:ARDM)   Watch this stock  
Find more results for ARDM
-0.13 (-10.00%)
Feb 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.15 - 1.29
52 week 0.78 - 7.35
Open 1.27
Vol / Avg. 0.00/629,896.00
Mkt cap 17.72M
P/E     -
Div/yield     -
EPS -0.98
Shares 15.15M
Beta 0.81
Inst. own 38%
Mar 26, 2018
Q4 2017 Aradigm Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -142.45% -16891.28%
Operating margin -108.06% -15395.90%
EBITD margin - -15332.82%
Return on average assets -114.71% -108.56%
Return on average equity - -273.38%
Employees 23 -
CDP Score - -


3929 Point Eden Way
HAYWARD, CA 94545-3720
United States - Map
+1-510-2659000 (Phone)
+1-510-2658878 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.

Officers and directors

John M. Siebert Ph.D. Executive Chairman of the Board, Interim Principal Executive Officer
Age: 77
Bio & Compensation  - Reuters
Virgil D. Thompson Independent Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
David Bell Director
Age: 61
Bio & Compensation  - Reuters
Frederick M. Hudson CPA Independent Director
Age: 71
Bio & Compensation  - Reuters